GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orphazyme AS (CHIX:ORPHAc) » Definitions » EPS (Diluted)

Orphazyme AS (CHIX:ORPHAC) EPS (Diluted) : kr0.00 (TTM As of Jun. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Orphazyme AS EPS (Diluted)?

Orphazyme AS's Earnings per Share (Diluted) for the three months ended in Jun. 2022 was kr0.00. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 was kr0.00.

Orphazyme AS's EPS (Basic) for the three months ended in Jun. 2022 was kr0.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2022 was kr0.00.

Orphazyme AS's EPS without NRI for the three months ended in Jun. 2022 was kr0.00. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2022 was kr0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.


Orphazyme AS EPS (Diluted) Historical Data

The historical data trend for Orphazyme AS's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orphazyme AS EPS (Diluted) Chart

Orphazyme AS Annual Data
Trend Jun14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
EPS (Diluted)
Get a 7-Day Free Trial -10,430.00 -11,470.00 -16,850.00 -22,320.00 -17,940.00

Orphazyme AS Quarterly Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Orphazyme AS's EPS (Diluted)

For the Biotechnology subindustry, Orphazyme AS's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orphazyme AS's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Orphazyme AS's PE Ratio distribution charts can be found below:

* The bar in red indicates where Orphazyme AS's PE Ratio falls into.



Orphazyme AS EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Orphazyme AS's Diluted EPS for the fiscal year that ended in Dec. 2021 is calculated as

Diluted EPS (A: Dec. 2021 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-626.539-0)/0.035
=-17,901.11

Orphazyme AS's Diluted EPS for the quarter that ended in Jun. 2022 is calculated as

Diluted EPS (Q: Jun. 2022 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(62.983-0)/0.035
=1,799.51

EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Orphazyme AS  (CHIX:ORPHAc) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Orphazyme AS EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Orphazyme AS's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Orphazyme AS (CHIX:ORPHAC) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Ole Maaloes Vej 3, Copenhagen, DNK, DK-2200
Orphazyme AS is a late-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutics for the treatment of neurodegenerative rare diseases. The company's lead candidate, Arimoclomol, is in development for severe orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), and Inclusion Body Myositis (IBM).

Orphazyme AS (CHIX:ORPHAC) Headlines

No Headlines